Robert Nelsen - Net Worth and Insider Trading

Robert Nelsen Net Worth

The estimated net worth of Robert Nelsen is at least $1.6 Billion dollars as of 2024-04-27. Robert Nelsen is the Director, 10% Owner of Karuna Therapeutics Inc and owns about 3,362,872 shares of Karuna Therapeutics Inc (KRTX) stock worth over $1.1 Billion. Robert Nelsen is the Director, 10% Owner of Vir Biotechnology Inc and owns about 28,666,663 shares of Vir Biotechnology Inc (VIR) stock worth over $236 Million. Robert Nelsen is also the Director, 10% Owner of Juno Therapeutics Inc and owns about 1,097,015 shares of Juno Therapeutics Inc (JUNO) stock worth over $95 Million. Besides these, Robert Nelsen also holds Sana Biotechnology Inc (SANA) , Prime Medicine Inc (PRME) , Alnylam Pharmaceuticals Inc (ALNY) , Fate Therapeutics Inc (FATE) , Agios Pharmaceuticals Inc (AGIO) , Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Robert Nelsen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Robert Nelsen has not made any transactions after 2024-02-15 and currently still holds the listed stock(s).

Transaction Summary of Robert Nelsen

To

Robert Nelsen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert Nelsen owns 40 companies in total, including Codiak BioSciences Inc (CDAKQ) , Metacrine Inc (MTCR) , and Unity Biotechnology Inc (UBX) among others .

Click here to see the complete history of Robert Nelsen’s form 4 insider trades.

Insider Ownership Summary of Robert Nelsen

Ticker Comapny Transaction Date Type of Owner
CDAKQ Codiak BioSciences Inc 2020-10-13 10 percent owner
MTCR Metacrine Inc 2020-09-15 10 percent owner
UBX Unity Biotechnology Inc 2020-06-18 director
KRTX Karuna Therapeutics Inc 2019-07-02 director & 10 percent owner
DNLI Denali Therapeutics Inc 2019-08-08 director & 10 percent owner
VIR Vir Biotechnology Inc 2021-03-30 director & 10 percent owner
BEAM Beam Therapeutics Inc 2020-02-05 director & 10 percent owner
SYRS Syros Pharmaceuticals Inc 2019-03-07 10 percent owner
FIXX Homology Medicines Inc 2018-03-27 10 percent owner
SNNAQ Sienna Biopharmaceuticals Inc 2019-02-22 10 percent owner
GOSS Gossamer Bio Inc 2019-02-07 10 percent owner
TWST Twist Bioscience Corp 2018-11-02 10 percent owner
SRRK Scholar Rock Holding Corp 2018-05-23 10 percent owner
PULM Pulmatrix Inc 2018-04-03 other: Former 10% owner
JUNO Juno Therapeutics Inc 2018-03-05 director
QTRX Quanterix Corp 2020-11-20 10 percent owner
AGIO Agios Pharmaceuticals Inc 2017-03-06 director & 10 percent owner
XCOMQ Xtera Communications Inc 2016-10-11 10 percent owner
PI Impinj Inc 2016-07-20 10 percent owner
PZRXQ PhaseRx Inc 2016-05-23 10 percent owner
SAGE Sage Therapeutics Inc 2015-01-14 director & 10 percent owner
IOTS Adesto Technologies Corp 2015-10-30 10 percent owner
BLPH Bellerophon Therapeutics Inc 2015-02-13 director & 10 percent owner
AKAOQ Achaogen Inc 2014-03-17 10 percent owner
FATE Fate Therapeutics Inc 2013-10-04 director & 10 percent owner
BLUE bluebird bio Inc 2013-06-18 10 percent owner
NGSX NeurogesX Inc 2012-06-07 director & 10 percent owner
CYCC Cyclacel Pharmaceuticals Inc 2005-06-17 director & 10 percent owner
ALNY Alnylam Pharmaceuticals Inc 2004-05-27 10 percent owner
ILMN Illumina Inc 2003-05-27 director
MASS 908 Devices Inc 2020-12-17 10 percent owner
ERAS Erasca Inc 2021-07-15 10 percent owner
SANA Sana Biotechnology Inc 2024-02-08 director
LYEL Lyell Immunopharma Inc 2021-06-16 director & 10 percent owner
VERV Verve Therapeutics Inc 2021-06-16 10 percent owner
REVHU Revolution Healthcare Acquisition Corp 2021-03-17 director
DALS DA32 Life Science Tech Acquisition Corp 2021-07-27 10 percent owner
REVH Revolution Healthcare Acquisition Corp 2021-03-17 director
PRME Prime Medicine Inc 2024-02-15 director & 10 percent owner
NMRA Neumora Therapeutics Inc 2023-09-14 10 percent owner

Robert Nelsen Latest Holdings Summary

Robert Nelsen currently owns a total of 9 stocks. Among these stocks, Robert Nelsen owns 3,362,872 shares of Karuna Therapeutics Inc (KRTX) as of July 2, 2019, with a value of $1.1 Billion and a weighting of 67.39%. Robert Nelsen owns 28,666,663 shares of Vir Biotechnology Inc (VIR) as of October 16, 2019, with a value of $236 Million and a weighting of 14.33%. Robert Nelsen also owns 1,097,015 shares of Juno Therapeutics Inc (JUNO) as of December 18, 2014, with a value of $95 Million and a weighting of 5.8%. The other 6 stocks Sana Biotechnology Inc (SANA) , Prime Medicine Inc (PRME) , Alnylam Pharmaceuticals Inc (ALNY) , Fate Therapeutics Inc (FATE) , Agios Pharmaceuticals Inc (AGIO) , Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 12.48% among all his current holdings.

Latest Holdings of Robert Nelsen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KRTX Karuna Therapeutics Inc 2019-07-02 3,362,872 329.83 1,109,176,072
VIR Vir Biotechnology Inc 2019-10-16 28,666,663 8.23 235,926,636
JUNO Juno Therapeutics Inc 2014-12-18 1,097,015 86.96 95,396,424
SANA Sana Biotechnology Inc 2024-02-08 10,315,103 8.72 89,947,698
PRME Prime Medicine Inc 2024-02-15 15,472,674 4.43 68,466,582
ALNY Alnylam Pharmaceuticals Inc 2004-05-27 222,500 143.31 31,886,475
FATE Fate Therapeutics Inc 2013-10-04 2,473,188 3.80 9,398,114
AGIO Agios Pharmaceuticals Inc 2017-03-06 109,230 31.49 3,439,653
SYRS Syros Pharmaceuticals Inc 2016-07-06 463,714 5.04 2,337,119

Holding Weightings of Robert Nelsen


Robert Nelsen Form 4 Trading Tracker

According to the SEC Form 4 filings, Robert Nelsen has made a total of 1 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Karuna Therapeutics Inc is the acquisition of 200,000 shares on July 2, 2019, which cost Robert Nelsen around $3 Million.

According to the SEC Form 4 filings, Robert Nelsen has made a total of 1 transactions in Vir Biotechnology Inc (VIR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Vir Biotechnology Inc is the acquisition of 1,000,000 shares on October 16, 2019, which cost Robert Nelsen around $20 Million.

According to the SEC Form 4 filings, Robert Nelsen has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 0 shares on December 18, 2014, which brought Robert Nelsen around $0.

More details on Robert Nelsen's insider transactions can be found in the Insider Trading History of Robert Nelsen table.

Insider Trading History of Robert Nelsen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Robert Nelsen Trading Performance

GuruFocus tracks the stock performance after each of Robert Nelsen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert Nelsen is -6.84%. GuruFocus also compares Robert Nelsen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert Nelsen within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Robert Nelsen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Robert Nelsen

Average Return

97.39%

Average return per transaction

Outperforming Transactions

60%

3 out of 5 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -0.78 -6.84 62.67 97.39 41.79 11.14
Relative Return to S&P 500(%) -3.9 -11.86 56.48 84.44 25.45 2.17

Robert Nelsen Ownership Network

Ownership Network List of Robert Nelsen

No Data

Ownership Network Relation of Robert Nelsen


Robert Nelsen Owned Company Details

What does Codiak BioSciences Inc do?

Who are the key executives at Codiak BioSciences Inc?

Robert Nelsen is the 10 percent owner of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .

Codiak BioSciences Inc (CDAKQ) Insider Trades Summary

Over the past 18 months, Robert Nelsen made no insider transaction in Codiak BioSciences Inc (CDAKQ). Other recent insider transactions involving Codiak BioSciences Inc (CDAKQ) include a net sale of 61,535 shares made by Douglas E Williams , a net sale of 20,226 shares made by Linda Bain , and a net sale of 17,534 shares made by Sriram Sathyanarayanan .

In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 129,081 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 129,081 shares.

Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Codiak BioSciences Inc Insider Transactions

No Available Data

Robert Nelsen Mailing Address

Above is the net worth, insider trading, and ownership report for Robert Nelsen. You might contact Robert Nelsen via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.

Discussions on Robert Nelsen

No discussions yet.